Suppr超能文献

毒性研究的剂量选择:确定最大可重复剂量的方案

Dose selection for toxicity studies: a protocol for determining the maximum repeatable dose.

作者信息

Spurling N W, Carey P F

机构信息

Development Division, Glaxo Group Research Ltd, Ware, Hertfordshire, UK.

出版信息

Hum Exp Toxicol. 1992 Nov;11(6):449-57. doi: 10.1177/096032719201100603.

Abstract
  1. A three-stage protocol is described for a dose-ranging study which defines the maximum repeatable dose (MRD) and provides a preview of the toxicology of new, pharmacologically active, substances before commencing the first formal regulatory toxicity studies, usually of 2 or 4 weeks duration. 2. Additionally, a range of toxicokinetic (TK) data relevant to protocol design for formal studies is generated. 3. Stage A is a dose incrementation process in which the MRD is provisionally determined and basic TK values generated. 4. In stage B the animals are dosed daily for at least 7 d, the MRD is substantiated and a wider range of TK data obtained. 5. In stage C, each of the dose levels identified for a formal study is administered once to investigate the relationship of doses to TK data. 6. This protocol can be completed using as few as 24 rats or six dogs (or primates). 7. Selection of dose levels for the first formal studies can be greatly aided by the results of a well-designed dose-ranging study including TK data. 8. For particularly toxic substances, the findings of studies based on this protocol have frequently been sufficiently clear to warrant early termination of their development.
摘要
  1. 描述了一种用于剂量范围研究的三阶段方案,该方案可确定最大可重复剂量(MRD),并在开始通常为期2或4周的首次正式监管毒性研究之前,对新的药理活性物质的毒理学进行初步评估。2. 此外,还会生成一系列与正式研究方案设计相关的毒代动力学(TK)数据。3. A阶段是剂量递增过程,在此过程中初步确定MRD并生成基本的TK值。4. 在B阶段,动物每天给药至少7天,证实MRD并获得更广泛的TK数据。5. 在C阶段,对正式研究确定的每个剂量水平给药一次,以研究剂量与TK数据之间的关系。6. 使用少至24只大鼠或6只狗(或灵长类动物)即可完成该方案。7. 精心设计的包括TK数据的剂量范围研究结果,可极大地帮助选择首次正式研究的剂量水平。8. 对于特别有毒的物质,基于该方案的研究结果通常足够明确,足以保证提前终止其研发。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验